دورية أكاديمية
Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
| العنوان: | Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use |
|---|---|
| المؤلفون: | Ganiyu Olatunbosun Arinola, Issa Abdullahi, Sheu Kadiri Rahamon, Zainab Bolanle Fasasi, Olajumoke Oluwaseun Adedeji, Adigun Kehinde, Adekunle Akeem Bakare |
| المصدر: | The Egyptian Journal of Bronchology, Vol 17, Iss 1, Pp 1-6 (2023) |
| بيانات النشر: | SpringerOpen, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Diseases of the respiratory system LCC:Medical emergencies. Critical care. Intensive care. First aid |
| مصطلحات موضوعية: | Asthma, COVID-19, Indoleamine-2, 3-Dioxygenase, Pulmonary tuberculosis, Tryptophan, Diseases of the respiratory system, RC705-779, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9 |
| الوصف: | Abstract Background Clinical trial of IDO inhibitor or uses of micro-nutrient supplements during management of diseases is commonly done without having adequate basis for the practise. Tryptophan (Trp) is an essential amino acid needed for T-lymphocyte function, and indoleamine-2,3-dioxygenase (IDO) is a potent immunoregulatory molecule that catalyses the rate-limiting step of Trp degradation in the kynurenine (Kyn) pathway. Materials and methods Human IDO in the plasma samples was measured using ELISA in patients with non-infectious (asthma) and infectious diseases (pulmonary tuberculosis and COVID-19) compared with corresponding un-infected controls. Results Mean IDO activity in COVID-19 patients was significantly higher compared with corresponding control (p = 0.001) while mean IDO activity in pulmonary tuberculosis patients was non-significantly higher compared with corresponding control (p = 0.520), and mean IDO activity in asthma patients was non-significantly lower compared with corresponding control (p = 0.102). Conclusion Our data suggest that IDO activity as an innate immune factor is increased in infectious lung diseases (COVID-19 and pulmonary tuberculosis) but reduced in non-infectious disease (asthma) and that use of tryptophan supplementation or IDO inhibitor may not be necessary in all lung diseases. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2314-8551 |
| العلاقة: | https://doaj.org/toc/2314-8551Test |
| DOI: | 10.1186/s43168-022-00174-2 |
| الوصول الحر: | https://doaj.org/article/ebd7ca0cd7b047d0a1dddb6e4d9c9a15Test |
| رقم الانضمام: | edsdoj.bd7ca0cd7b047d0a1dddb6e4d9c9a15 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 23148551 |
|---|---|
| DOI: | 10.1186/s43168-022-00174-2 |